大行評級|高盛:下調百威亞太目標價至9港元 維持“買入”評級
高盛研究報吿指,百威亞太即將公佈次季業績,該行預期次季集團整體內生收入(organic revenue)跌6.9%,經調整EBITDA跌12.6%,淨利潤錄2.16億美元,而去年同期為2.54億美元;展望第三季及下半年,預期盈利增長會慢慢恢復。至於全年,該行料亞太東部地區內生EBITDA升2.2%,由平均售價上升及銷量增長推動;亞太西部地區內生EBITDA則按年跌5.7%,但消費者情緒將逐漸恢復。該行對其目標價由9.2港元下調至9港元,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.